Wanbury Receives ANVISA Approval for Metformin HCl API
Wanbury Ltd 路 Press Release 路 12 Nov 2026, 4:57 pm
Wanbury Receives ANVISA Approval for Metformin HCl API Wanbury Limited secured regulatory approval (CADIFA: Letter of Suitability for API) from Brazil's ANVISA for its flagship product, Metformin HCl EP grade, on 12th Nov'26. Marking the company's third consecutive ANVISA approval, this clearance enables pharmaceutical customers to utilize Wanbury's API for formulation manufacturing in Brazil. Following the approval, the company has initiated commercial discussions with multiple clients to scale up business volumes in the region.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. 路 30 Oct 2026
- Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the un-audited Financial Results (Standalone .... 路 04 Nov 2026
